Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes

We appreciate Dr. Woo's response to our study (1) and his comparison (2) of the Canadian Diabetes Association (CDA) clinical practice guidelines and the American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) consensus algorithm and welcome the opportunity to address the differences he has identified. The original ADA/EASD consensus algorithm and the subsequent revisions were developed independently by the consensus group and were then presented to the two major diabetes organizations for their review and approval of the process. Dr. Woo notes the CDA's process of data review with a “standardized evidence-based approach” and the participation of “over 90 authors and a steering committee of 18” and concludes that the process removed “as much bias as possible,” implying that this approach was superior to our consensus algorithm process. He further notes …

[1]  Michael E. Miller,et al.  Effects of intensive glucose lowering in type 2 diabetes. , 2008, The New England journal of medicine.

[2]  W. Pories,et al.  Who Would Have Thought It? An Operation Proves to Be the Most Effective Therapy for Adult‐Onset Diabetes Mellitus , 1995, Annals of surgery.

[3]  C. D. Miller,et al.  Hypoglycemia in patients with type 2 diabetes mellitus. , 2001, Archives of internal medicine.

[4]  L. Bouter,et al.  Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin: a systematic review. , 2005, Diabetes care.

[5]  Grant D. Huang,et al.  Glucose control and vascular complications in veterans with type 2 diabetes. , 2009, The New England journal of medicine.

[6]  G. Bray,et al.  Reduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes , 2007, Diabetes Care.

[7]  D. Nathan.  Rosiglitazone and cardiotoxicity--weighing the evidence. , 2007, The New England journal of medicine.

[8]  Yoon K Loke,et al.  Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. , 2007, JAMA.

[9]  C. van Weel,et al.  Alpha-glucosidase inhibitors for type 2 diabetes mellitus. , 2005, The Cochrane database of systematic reviews.

[10]  V. Woo.  Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes , 2009, Diabetes Care.

[11]  Erland Erdmann,et al.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.

[12]  S. Brunton.  Initiating insulin therapy in type 2 diabetes: benefits of insulin analogs and insulin pens. , 2008, Diabetes technology & therapeutics.

[13]  B. Zinman,et al.  Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy , 2009, Diabetes Care.

[14]  M. Sheehan.  Current therapeutic options in type 2 diabetes mellitus: a practical approach. , 2003, Clinical medicine & research.

[15]  B. Zinman,et al.  Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. , 2006, The New England journal of medicine.

[16]  L. Ryysy,et al.  Comparison of Bedtime Insulin Regimens in Patients with Type 2 Diabetes Mellitus , 1999, Annals of Internal Medicine.

[17]  J. Leahy.  Effect of Initial Combination Therapy With Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients With Type 2 Diabetes , 2008 .

[18]  A. Holstein,et al.  Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide , 2001, Diabetes/metabolism research and reviews.

[19]  A. Morabito,et al.  Laparoscopic gastric banding prevents type 2 diabetes and arterial hypertension and induces their remission in morbid obesity: a 4-year case-controlled study. , 2005, Diabetes care.

[20]  R. Heine,et al.  Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes , 2005, Annals of Internal Medicine.

[21]  P. Raskin,et al.  PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. , 2005, Diabetes care.

[22]  B. Glaser,et al.  Induction of Long-Term Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients by Transient Intensive Insulin Treatment , 1997, Diabetes Care.

[23]  Neil J Stone,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.

[24]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[25]  E. Kilpatrick,et al.  Establishing pragmatic estimated GFR thresholds to guide metformin prescribing , 2007, Diabetic medicine : a journal of the British Diabetic Association.

[26]  C. Meinert,et al.  A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. , 1970, Diabetes.

[27]  H. Jick,et al.  Use of thiazolidinediones and fracture risk. , 2008, Archives of internal medicine.

[28]  J. Rungby,et al.  Amylin agonists: a novel approach in the treatment of diabetes. , 2004, Diabetes.

[29]  Dennis D. Kim,et al.  Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. , 2005, Diabetes care.

[30]  E. A. Wilson,et al.  Maturity onset diabetes mellitus: response to intensive dietary management. , 1975, British medical journal.

[31]  D. Nathan.  Initial Management of Glycemia in Type 2 Diabetes Mellitus , 2002 .

[32]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[33]  D L DeMets,et al.  Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. , 1988, JAMA.

[34]  J. Levy,et al.  U.K. Prospective Diabetes Study 16: Overview of 6 Years' Therapy of Type II Diabetes: A Progressive Disease , 1995, Diabetes.

[35]  Elizabeth Goyder,et al.  Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial , 2007, BMJ : British Medical Journal.

[36]  B. Zinman,et al.  Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy , 2008, Diabetes Care.

[37]  P. Cryer,et al.  Hypoglycemia in type 2 diabetes. , 2004, The Medical clinics of North America.

[38]  S. Nissen,et al.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.

[39]  S. Genuth.  Insulin Use in NIDDM , 1990, Diabetes Care.

[40]  M. Hanefeld,et al.  Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus , 2006, Diabetologia.

[41]  E. Salpeter,et al.  Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. , 2002, The Cochrane database of systematic reviews.

[42]  R. DeFronzo,et al.  Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. , 1995, The New England journal of medicine.

[43]  A. Lincoff,et al.  Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. , 2007, JAMA.

[44]  S. Schwartz,et al.  Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: efficacy, safety, and cost analysis. , 2003, Diabetes care.

[45]  E. Salpeter,et al.  Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. , 2003, The Cochrane database of systematic reviews.

[46]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .

[47]  Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report , 2009, Diabetes, obesity & metabolism.

[48]  H. Chase,et al.  Glucose control and the renal and retinal complications of insulin-dependent diabetes. , 1989, JAMA.

[49]  Markolf Hanefeld,et al.  Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. , 2003, JAMA.

[50]  S. Fowler,et al.  Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. , 2005, Diabetes care.

[51]  Margaret Anderson,et al.  Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. , 2008, JAMA.

[52]  P. Ambery,et al.  Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes , 2009, Diabetes Care.

[53]  G. Jean-Louis,et al.  Rosiglitazone evaluated for cardiovascular outcomes – an interim analysis , 2007 .

[54]  P. Reichard,et al.  The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. , 1993, The New England journal of medicine.

[55]  H. Tian,et al.  Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial , 2008, The Lancet.

[56]  R. Holman,et al.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.

[57]  I. Hirsch,et al.  A Real-World Approach to Insulin Therapy in Primary Care Practice , 2005 .

[58]  J. S. St. Peter,et al.  A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. , 2002, Diabetes care.

[59]  Dennis D. Kim,et al.  Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. , 2005, Diabetes care.

[60]  Claude Bouchard,et al.  Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. , 2004, The New England journal of medicine.

[61]  M. Hanefeld,et al.  Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. , 2007, The New England journal of medicine.

[62]  S. Schinner.  Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes , 2009 .

[63]  J. Lau,et al.  Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. , 2007, JAMA.

[64]  Maximal dose glyburide therapy in markedly symptomatic patients with type 2 diabetes: a new use for an old friend. , 1996, The Journal of clinical endocrinology and metabolism.

[65]  P. Clauson,et al.  A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients. , 1999, Diabetes care.

[66]  D. Eizirik.  Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes , 2009, Diabetes Care.

[67]  D. Nathan.  Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes , 2009, Diabetes Care.

[68]  L. Groop.  Sulfonylureas in NIDDM , 1992, Diabetes Care.

[69]  B. Richter,et al.  Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. , 2008, The Cochrane database of systematic reviews.

[70]  A. Berghold,et al.  Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. , 2007, The Cochrane database of systematic reviews.

[71]  N. Marchionni,et al.  Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: a meta-analysis. , 2008, Diabetes research and clinical practice.

[72]  Alfonso T. Perez,et al.  A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. , 2005, Diabetes care.

[73]  D. Nathan.  Finding new treatments for diabetes--how many, how fast... how good? , 2007, The New England journal of medicine.

[74]  J. Godine,et al.  Glyburide or insulin for metabolic control in non-insulin-dependent diabetes mellitus. A randomized, double-blind study. , 1988, Annals of internal medicine.

[75]  G L Myers,et al.  The national glycohemoglobin standardization program: a five-year progress report. , 2001, Clinical chemistry.

[76]  R. Holman,et al.  Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: U.K. prospective diabetes study 61. , 2002, Diabetes care.

[77]  J. Rosenstock,et al.  Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. , 2004, Diabetes care.

[78]  S. Colagiuri,et al.  The Diabetes Control and Complications Trial , 1983, Henry Ford Hospital medical journal.

[79]  D. Drucker.  Biologic actions and therapeutic potential of the proglucagon-derived peptides , 2005, Nature Clinical Practice Endocrinology &Metabolism.

[80]  Shari Bolen,et al.  Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus , 2007, Annals of Internal Medicine.

[81]  J. Rosenstock,et al.  Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. , 2004, Diabetes care.

[82]  B. Zinman,et al.  Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy , 2006, Diabetes Care.